Pacira BioSciences (PCRX) Liabilities and Shareholders Equity (2010 - 2026)

Pacira BioSciences' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 23.83% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $5.3 billion (down 15.86% YoY), while the FY2025 annual figure was $1.3 billion, down 18.58% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.2 billion, down from $1.3 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.9 billion in Q1 2022, with the low at $1.2 billion in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.6 billion (2024), against an average of $1.6 billion.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity soared 46.91% in 2022, then slipped 23.83% in 2026.
• Pacira BioSciences' Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then fell by 6.35% to $1.6 billion in 2023, then retreated by 1.33% to $1.6 billion in 2024, then declined by 18.58% to $1.3 billion in 2025, then dropped by 4.46% to $1.2 billion in 2026.
• Business Quant data shows PCRX's Liabilities and Shareholders Equity at $1.2 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.